βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel
- PMID: 28567478
- DOI: 10.1007/s00280-017-3345-2
βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel
Abstract
Cabazitaxel is a novel taxane approved for treatment of metastatic hormone-refractory prostate cancer in patients pretreated with docetaxel. Cabazitaxel, docetaxel, and paclitaxel bind specifically to tubulin in microtubules, disrupting functions essential to tumor growth. High levels of βIII-tubulin isotype expression are associated with tumor aggressivity and drug resistance. To understand cabazitaxel's increased efficacy, we examined binding of radio-labeled cabazitaxel and docetaxel to microtubules and the drugs' suppression of microtubule dynamic instability in vitro in microtubules assembled from purified bovine brain tubulin containing or devoid of βIII-tubulin. We found that cabazitaxel suppresses microtubule dynamic instability significantly more potently in the presence of βIII-tubulin than in its absence. In contrast, docetaxel showed no βIII-tubulin-enhanced microtubule stabilization. We also asked if the selective potency of cabazitaxel on βIII-tubulin-containing purified microtubules in vitro extends to cabazitaxel's effects in human tumor cells. Using MCF7 human breast adenocarcinoma cells, we found that cabazitaxel also suppressed microtubule shortening rates, shortening lengths, and dynamicity significantly more strongly in cells with normal levels of βIII-tubulin than after 50% reduction of βIII-tubulin expression by siRNA knockdown. Cabazitaxel also more strongly induced mitotic arrest in MCF7 cells with normal βIII-tubulin levels than after βIII-tubulin reduction. In contrast, docetaxel had little or no βIII-tubulin-dependent selective effect on microtubule dynamics or mitotic arrest. The selective potency of cabazitaxel on purified βIII-tubulin-containing microtubules and in cells expressing βIII-tubulin suggests that cabazitaxel may be unusual among microtubule-targeted drugs in its superior anti-tumor efficacy in tumors overexpressing βIII-tubulin.
Keywords: Cabazitaxel; Docetaxel; Microtubule; Taxane; Tubulin; βIII-tubulin.
Similar articles
-
Antiproliferative mechanism of action of the novel taxane cabazitaxel as compared with the parent compound docetaxel in MCF7 breast cancer cells.Mol Cancer Ther. 2014 Aug;13(8):2092-103. doi: 10.1158/1535-7163.MCT-14-0265. Epub 2014 Jun 30. Mol Cancer Ther. 2014. PMID: 24980947
-
Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype.Cancer Chemother Pharmacol. 2015 Nov;76(5):1013-24. doi: 10.1007/s00280-015-2863-z. Epub 2015 Sep 28. Cancer Chemother Pharmacol. 2015. PMID: 26416565
-
Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin.Mol Cancer Ther. 2010 May;9(5):1339-48. doi: 10.1158/1535-7163.MCT-09-0679. Epub 2010 May 4. Mol Cancer Ther. 2010. PMID: 20442307
-
βIII-Tubulin: biomarker of taxane resistance or drug target?Expert Opin Ther Targets. 2013 Apr;17(4):461-72. doi: 10.1517/14728222.2013.766170. Epub 2013 Feb 2. Expert Opin Ther Targets. 2013. PMID: 23379899 Review.
-
Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies.Mol Cancer Ther. 2009 Jan;8(1):17-25. doi: 10.1158/1535-7163.MCT-08-0986. Mol Cancer Ther. 2009. PMID: 19139109 Review.
Cited by
-
Nuclear βII-Tubulin and its Possible Utility in Cancer Diagnosis, Prognosis and Treatment.Front Cell Dev Biol. 2022 May 30;10:870088. doi: 10.3389/fcell.2022.870088. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35706904 Free PMC article.
-
The past and present of prostate cancer and its treatment and diagnostics: A historical review.SAGE Open Med. 2023 Dec 1;11:20503121231216837. doi: 10.1177/20503121231216837. eCollection 2023. SAGE Open Med. 2023. PMID: 38050625 Free PMC article. Review.
-
Quantification of Engagement of Microtubules by Small Molecules in Living Cells by Flow Cytometry.ACS Bio Med Chem Au. 2022 Oct 19;2(5):529-537. doi: 10.1021/acsbiomedchemau.2c00031. Epub 2022 Aug 9. ACS Bio Med Chem Au. 2022. PMID: 36281300 Free PMC article.
-
Deciphering the molecular landscape: integrating single-cell transcriptomics to unravel myofibroblast dynamics and therapeutic targets in clear cell renal cell carcinomas.Front Immunol. 2024 Mar 18;15:1374931. doi: 10.3389/fimmu.2024.1374931. eCollection 2024. Front Immunol. 2024. PMID: 38562930 Free PMC article.
-
Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer.Oncotarget. 2017 Nov 30;8(67):111225-111245. doi: 10.18632/oncotarget.22760. eCollection 2017 Dec 19. Oncotarget. 2017. PMID: 29340049 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources